1 Cho NH, Shaw JE, Karuranga S, et al.IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045.Diabetes Res Clin Pract,2018,138:271-281.
2 Addendum. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2020. Diabetes Care 2020;43(Suppl. 1):S111-S134.Diabetes Care,2020,43(8):1977-1978.
3 Van Gaal LF, Mertens IL, De Block CE.Mechanisms linking obesity with cardiovascular disease.Nature,2006,444(7121):875-880.
4 Zhang L, Chen C, Zhou N, et al.Circulating asprosin concentrations are increased in type 2 diabetes mellitus and independently associated with fasting glucose and triglyceride.Clin Chim Acta,2019,489:183-188.
5 Acara AC, Bolatkale M, Kızıloğlu İ, et al.A novel biochemical marker for predicting the severity of ACS with unstable angina pectoris: Asprosin.Am J Emerg Med,2018,36(8):1504-1505.
6 Romere C, Duerrschmid C, Bournat J, et al.Asprosin, a Fasting-Induced Glucogenic Protein Hormone.Cell,2016,165(3):566-579.
7 Duerrschmid C, He Y, Wang C, et al.Asprosin is a centrally acting orexigenic hormone.Nat Med,2017,23(12):1444-1453.
8 Jung TW, Kim HC, Kim HU, et al.Asprosin attenuates insulin signaling pathway through PKCδ-activated ER stress and inflammation in skeletal muscle.J Cell Physiol,2019,234(11):20888-20899.
9 Wen MS, Wang CY, Yeh JK, et al.The role of Asprosin in patients with dilated cardiomyopathy.BMC Cardiovasc Disord,2020,20(1):402.
10 Zhang Z, Tan Y, Zhu L, et al.Asprosin improves the survival of mesenchymal stromal cells in myocardial infarction by inhibiting apoptosis via the activated ERK1/2-SOD2 pathway.Life Sci,2019,231:116554.
11 Vallon V.The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.Annu Rev Med,2015,66:255-270.
12 Aronson R, Frias J, Goldman A, et al.Long-term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study.Diabetes Obes Metab,2018,20(6):1453-1460.
13 Cefalu WT, Leiter LA, Yoon KH, et al.Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.Lancet,2013,382(9896):941-950.
14 Bailey CJ, Gross JL, Pieters A, et al.Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.Lancet,2010,375(9733):2223-2233.
15 Cai X, Yang W, Gao X, et al.The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis.Obesity (Silver Spring),2018,26(1):70-80.
16 Heerspink HJ, Perkins BA, Fitchett DH, et al.Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.Circulation,2016,134(10):752-772.
17 Packer M.Do sodium-glucose co-transporter-2 inhibitors prevent heart failure with a preserved ejection fraction by counterbalancing the effects of leptin? A novel hypothesis.Diabetes Obes Metab,2018,20(6):1361-1366.
18 Garvey WT, Van Gaal L, Leiter LA, et al.Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes.Metabolism,2018,85:32-37.
19 Metcalf PA, Scragg RK.Comparison of WHO and ADA criteria for diagnosis of glucose status in adults.Diabetes Res Clin Pract,2000,49(2-3):169-180.
20 Zhang X, Jiang H, Ma X, et al.Increased serum level and impaired response to glucose fluctuation of asprosin is associated with type 2 diabetes mellitus.J Diabetes Investig,2020,11(2):349-355.
21 Li E, Shan H, Chen L, et al.OLFR734 Mediates Glucose Metabolism as a Receptor of Asprosin.Cell Metab,2019,30(2):319-328.e318.
22 Xu L, Nagata N, Nagashimada M, et al.SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice.EBioMedicine,2017,20:137-149.
23 Rosenstock J, Vico M, Wei L, et al.Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy.Diabetes Care,2012,35(7):1473-1478.
24 Yoshida A, Matsubayashi Y, Nojima T, et al.Attenuation of Weight Loss Through Improved Antilipolytic Effect in Adipose Tissue Via the SGLT2 Inhibitor Tofogliflozin.J Clin Endocrinol Metab,2019,104(9):3647-3660.
25 Poirier P, Giles TD, Bray GA, et al.Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism.Circulation,2006,113(6):898-918.
26 Kocaman N, Kuloğlu T.Expression of asprosin in rat hepatic, renal, heart, gastric, testicular and brain tissues and its changes in a streptozotocin-induced diabetes mellitus model.Tissue Cell,2020,66:101397.
27 McMurray JJV, Solomon SD, Inzucchi SE, et al.Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.N Engl J Med,2019,381(21):1995-2008.
28 Zinman B, Wanner C, Lachin JM, et al.Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.N Engl J Med,2015,373(22):2117-2128.
29 Cherney DZ, Odutayo A, Aronson R, et al.Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week.J Am Coll Cardiol,2019,74(20):2511-2524.
30 Wang Y, Xu L, Yuan L, et al.Sodium-glucose co-transporter-2 inhibitors suppress atrial natriuretic peptide secretion in patients with newly diagnosed Type 2 diabetes.Diabet Med,2016,33(12):1732-1736.
31 Feng X, Gu Q, Gao G, et al.The plasma levels of atrial natriuretic peptide and brain natriuretic peptide in type 2 diabetes treated with sodium-glucose cotransporter-2 inhibitor.Ann Endocrinol (Paris),2020,81(5):476-481.
32 Fasshauer M, Blüher M.Adipokines in health and disease.Trends Pharmacol Sci,2015,36(7):461-470.